The prevalence of antinuclear antibodies in patients with schizophrenia spectrum disorders: results from a large cohort study

Hans C van Mierlo; Lot de Witte; Ronald Hwm Derksen; Henny G Otten

doi:10.1038/npjschz.2015.13

The prevalence of antinuclear antibodies in patients with schizophrenia spectrum disorders: results from a large cohort study

Hans C van Mierlo, Lot de Witte, Ronald Hwm Derksen, Henny G Otten,

Research output: Contribution to journal › Article › Academic › peer-review

3 Citations (Scopus)

Abstract

BACKGROUND: An increased prevalence of autoantibodies has been found in patients with schizophrenia, suggesting a role for autoimmunity in schizophrenia pathogenesis. METHODS: We examined the presence of antinuclear antibodies (ANAs), with further determination of specific antibodies, in 368 patients with a schizophrenia spectrum disorder and 283 healthy controls. RESULTS: No significant difference in prevalence of ANAs between patients (8%) and controls (11%) was found. CONCLUSION: We did not find an association between ANAs and schizophrenia spectrum disorders. We discuss potential reasons for the discrepancy with some previous studies, such as inclusion of patients using chlorpromazine, which can induce ANAs.

Original language	English
Article number	15013
Journal	npj Schizophrenia
Volume	1
Issue number	1
DOIs	https://doi.org/10.1038/npjschz.2015.13 https://doi.org/10.1038/npjschz.2015.13
Publication status	Published - 2015

Keywords

Journal Article

Access to Document

Cite this

@article{f5d7ef34324a4fb69311cb504fe47ab1,

title = "The prevalence of antinuclear antibodies in patients with schizophrenia spectrum disorders: results from a large cohort study",

abstract = "BACKGROUND: An increased prevalence of autoantibodies has been found in patients with schizophrenia, suggesting a role for autoimmunity in schizophrenia pathogenesis. METHODS: We examined the presence of antinuclear antibodies (ANAs), with further determination of specific antibodies, in 368 patients with a schizophrenia spectrum disorder and 283 healthy controls. RESULTS: No significant difference in prevalence of ANAs between patients (8%) and controls (11%) was found. CONCLUSION: We did not find an association between ANAs and schizophrenia spectrum disorders. We discuss potential reasons for the discrepancy with some previous studies, such as inclusion of patients using chlorpromazine, which can induce ANAs.",

keywords = "Journal Article",

author = "{van Mierlo}, {Hans C} and {de Witte}, Lot and Derksen, {Ronald Hwm} and Otten, {Henny G}",

year = "2015",

doi = "10.1038/npjschz.2015.13",

language = "English",

volume = "1",

number = "1",

}

TY - JOUR

T1 - The prevalence of antinuclear antibodies in patients with schizophrenia spectrum disorders

T2 - results from a large cohort study

AU - van Mierlo, Hans C

AU - de Witte, Lot

AU - Derksen, Ronald Hwm

AU - Otten, Henny G

PY - 2015

Y1 - 2015

N2 - BACKGROUND: An increased prevalence of autoantibodies has been found in patients with schizophrenia, suggesting a role for autoimmunity in schizophrenia pathogenesis. METHODS: We examined the presence of antinuclear antibodies (ANAs), with further determination of specific antibodies, in 368 patients with a schizophrenia spectrum disorder and 283 healthy controls. RESULTS: No significant difference in prevalence of ANAs between patients (8%) and controls (11%) was found. CONCLUSION: We did not find an association between ANAs and schizophrenia spectrum disorders. We discuss potential reasons for the discrepancy with some previous studies, such as inclusion of patients using chlorpromazine, which can induce ANAs.

AB - BACKGROUND: An increased prevalence of autoantibodies has been found in patients with schizophrenia, suggesting a role for autoimmunity in schizophrenia pathogenesis. METHODS: We examined the presence of antinuclear antibodies (ANAs), with further determination of specific antibodies, in 368 patients with a schizophrenia spectrum disorder and 283 healthy controls. RESULTS: No significant difference in prevalence of ANAs between patients (8%) and controls (11%) was found. CONCLUSION: We did not find an association between ANAs and schizophrenia spectrum disorders. We discuss potential reasons for the discrepancy with some previous studies, such as inclusion of patients using chlorpromazine, which can induce ANAs.

KW - Journal Article

UR - http://www.scopus.com/inward/record.url?scp=85052699577&partnerID=8YFLogxK

U2 - 10.1038/npjschz.2015.13

DO - 10.1038/npjschz.2015.13

M3 - Article

C2 - 27336030

SN - 2334-265X

VL - 1

JO - npj Schizophrenia

JF - npj Schizophrenia

IS - 1

M1 - 15013

ER -

The prevalence of antinuclear antibodies in patients with schizophrenia spectrum disorders: results from a large cohort study

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this